ArticlePLoS neglected tropical diseases2026
Paragonimus proliferus Metacercaria-derived antigens mitigate DSS-Induced Ulcerative Colitis via immunomodulation and gut microbiota reconfiguration.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel illness with few treatment options, which means that new ways to treat it are needed. This study examined the protective effects and mechanisms of Paragonimus proliferus metacercaria-derived antigens (PmAg) in a dextran sulfate sodium (DSS)-induced mouse ulcerative colitis model. We discovered that intraperitoneal delivery of PmAg substantially mitigated colitis severity, as demonstrated by decreased weight loss, lower disease activity index scores, maintained colon length, and enhanced histopathological findings. Mechanistically, PmAg inhibited pro-inflammatory cytokines (IL-1β, TNF-α), increased the anti-inflammatory cytokine IL-10, and bolstered antioxidant defenses (SOD, GSH). It also restored the integrity of the intestinal barrier by boosting the number of goblet cells and the expression of tight junction proteins (Occludin, Claudin-1), while stopping the activation of the nuclear factor-kappa B (NF-κB) signaling pathway. Moreover, 16S rRNA sequencing demonstrated that PmAg reinstated gut microbiota α-diversity, diminished pathogenic genera (e.g., Escherichia-Shigella), and enhanced beneficial taxa (e.g., Lachnospiraceae_NK4A136_group and Alistipes). Integrated fecal metabolomics research revealed that PmAg altered metabolic profiles, specifically as significantly enriched the primary bile acid biosynthesis pathway, alpha-Linolenic acid metabolism pathway and Ubiquinone and other terpenoid-quinone biosynthesis pathways. In conclusion, our results suggested that PmAg could mitigates experimental colitis in mice by anti-inflammatory, improving gut microbiota and modulating fecal metabolomics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.